PDF factsheet
      Z

myocardial revascularization in acute myocardial infarction for >6h from onset of symptoms, clinical trials results

late PTCA versus no PTCA
Horie et al, 1998
late revascularization by primary PTCA
versus
no PTCA
patients with initial Q-wave anterior myocardial infarction >24 hours after onset
Follow-up duration: 50 months, mean
TOAT, 2002
late revascularization (late intervention and stent to the LAD + medical therapy)
versus
conservative therapy (medical therapy)
symptom-free patients after acute myocardial infarction open
Follow-up duration: 12 months, fixed
TOMIIS, 1994
late PTCA
versus
no PTCA
patients with a recent, first Q-wave myocardial infarction and an occluded infarct-related coronary artery open
Follow-up duration: 4 months, fixed
DECOPI, 2004
percutaneous revascularization carried out 2-15 days after symptom onset
versus
medical treatment
patients with a first Q-wave myocardial infarction and an occluded infarct vessel open
Follow-up duration: 34 months, mean
Silva et al, 2005
percutaneous coronary intervention
versus
conservative therapy (no-PCI)
patients with occluded infarct-related artery between 12 h and 14 days post-anterior MI were open
Follow-up duration: 6 months, fixed
OAT, 2006
routine PCI and stenting
versus
optimal medical therapy alone
stable patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction and who met a high-risk criterion (open
Follow-up duration: 35 months, mean
TOSCA-2, 2006
NCT00025766
PCI with stenting
versus
optimal medical therapy alone
patients with an occluded native infarct-related artery 3 to 28 days after MI open
Follow-up duration: 12 months, fixed
streptokinase versus placebo
EMERAS (7-12h), 1993
intravenous streptokinase 1.5 MU
versus
placebo
patients presenting 7-12 h from symptom onsetdouble blind
t-PA versus placebo
LATE, 1993
intravenous alteplase (100 mg over 3 h)
versus
placebo
patients with symptoms and electrocardiographic criteria consistent with AMI between 6 and 24 h from symptom onsetdouble blind
Follow-up duration: 6 mo
TAMI 6, 1992
tissue-type plasminogen activator 100 mg over 2 hours
versus
placebo
patients with 6 to 24 hours of symptoms and ECG ST elevation double blind
Follow-up duration: 6 months
USA

  Options


in first

in second

  Filter